Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M.Y. Lee(University of Glasgow), Naveed Sattar(University of Glasgow), Katriona Brooksbank(British Heart Foundation), Pardeep S. Jhund(Copenhagen University Hospital), Paul Welsh, John J.V. McMurray(University of Glasgow), Iain Speirits(Ambulance Care (Sweden)), Patrick B. Mark(Queen Elizabeth University Hospital), Kenneth Mangion(British Heart Foundation), Catherine Labinjoh(Forth Valley Royal Hospital), Colin Berry(University of Glasgow), Kirsty Wetherall(MRC Biostatistics Unit), John G. Dreisbach(Golden Jubilee National Hospital), Victor Chong(University Hospital Crosshouse), Liz Coyle(British Heart Foundation), Clare Murphy(Forth Valley Royal Hospital), J Petrie(Glasgow Royal Infirmary), Vera Lennie(University Hospital Ayr), Aleksandra Radjenovic(British Heart Foundation), Colin J. Petrie(Monklands Hospital), Rosemary Woodward(Queen Elizabeth University Hospital), Ninian N. Lang(British Heart Foundation), Giles Roditi(Glasgow Royal Infirmary), Mark C. Petrie(British Heart Foundation)
Cited by 437
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k